Purchase 4-HO-MET
Discount program, second-order - 5%OFF, third-order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 4-HO-MET for sale
A lesser-known psychedelic substance is 4-HO-MET, 4-hydroxy-N-methyl-N-ethyltryptamine, melatonin, or methylcybin. This compound is a structural and functional analogue of psilocin and the 4-hydroxyl analogue of methylethyltryptamine (MET). It was initially created by the distinguished scientist Alexander Shulgin and described in his book TiHKAL (Tryptamines I Have Known and Loved). According to Shulgin's studies, the suggested dose ranges from 10 to 20 milligrams.
Due to its capacity to generate psilocin-like effects, such as distortions of colour, sound, and shape, 4-HO-MET has earned notoriety despite its relatively unknown status. However, as with many psychoactive drugs, knowledge about the pharmacological characteristics, metabolism, and toxicity of 4-HO-MET is scarce.
What is 4-HO-MET?
4-HO-MET is a lesser-known psychedelic substance that shares structural and functional similarities with psilocin. It is also known as melatonin and methylcybin on the street.
The History of 4-HO-MET
Alexander Shulgin initially synthesized 4-HO-MET, as reported in his book TiHKAL. Shulgin's contributions to the realm of psychedelics are highly known, and he is credited with synthesizing and researching over 200 hallucinogenic substances.
The Effects of 4-HO-MET
According to reports, 4-HO-MET produces comparable effects to psilocin, including distortions of colour, sound, and shape. Due to a lack of study and data, the entire scope of its impacts remains to be seen.
Dosage Recommendations
According to Alexander Shulgin's book TiHKAL, the suggested dose of 4-HO-MET is between 10 and 20 mg. Noting that a person's tolerance and response to psychoactive drugs might vary, it is always advisable to begin with, a smaller dose and gradually increase it to a comfortable level.
The Legal Status of 4-HO-MET
4-HO-legal MET's status differs by nation and jurisdiction. 4-HO-MET is a Schedule I controlled drug in the United States, making its manufacturing, possession, and distribution unlawful. In some countries, 4-HO-MET may not be legal; thus, it is vital to investigate and understand the rules in your region.
Safety Concerns and Precautions
Due to the lack of knowledge on the pharmacological characteristics, metabolism, and toxicity of 4-HO-MET, it is recommended to use this chemical with caution and a focus on safety. It is always advisable to receive psychoactive drugs from a reliable source and to use harm reduction strategies, such as starting with a low dose and having a sober trip companion present.
4-HO-MET is a lesser-known psychedelic drug that has acquired notoriety for its psilocin-like properties. Despite this substance's relative obscurity, it is essential to comprehend and respect its possible hazards and legality. This page intends to offer a complete overview of 4-HO-MET. However, it is always advisable to seek out further information and resources.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics